Results 151 to 160 of about 5,171 (266)
Renal Blood Flow and Renin Activity in Renal Venous Blood in Essential Hypertension [PDF]
, 1970 M. Donald Blaufox +4 more
openalex +1 more source
Nuclear Factor I‐B Delays Liver Fibrosis by Inhibiting Chemokine Ligand 5 Transcription
Advanced Science, EarlyView.This study identifies the transcription factor Nuclear Factor I‐B (NFIB) as a key suppressor of liver fibrosis. NFIB expression declines during hepatic stellate cell activation, and its overexpression reduces fibrosis in mice models. The mechanism involves NFIB directly repressing chemokine C─C motif ligand 5 (CCL5), thereby alleviating oxidative ...
Qianqian Chen +14 more
wiley +1 more source
Renal blood‐flow and glomerular filtration [PDF]
The Journal of Physiology, 1922 E B, Mayrs, J M, Watt
openaire +2 more sources
Parabiosis, Assembloids, Organoids (PAO)
Advanced Science, EarlyView.This review evaluates parabiosis, organoids, and assembloids as complementary disease models spanning systemic, organ, and multi‐organ levels. It highlights their construction strategies, applications, and current limitations, while emphasizing their integration with frontier technologies such as artificial intelligence, organ‐on‐a‐chip, CRISPR, and ...
Yang Hong +5 more
wiley +1 more source
Advanced Science, EarlyView.Elemene increases SPP expression by competitively binding with miR‐130a‐5p to suppress SPP mRNA degradation. This led to more antigen/MHC‐I complexes being expressed on the cell surface, which consequently facilitated the recognition and killing of HCC cells by CTLs and enhancing the antitumor immune efficacy of anti‐PD‐1.
Menglan Wang +18 more
wiley +1 more source
Features of Ocular Blood Flow in Malignant Arterial Hypertension of Renal Origin
, 2023 В М Шелудченко +4 more
openalex +2 more sources
Advanced Science, EarlyView.In this work, we showcased two significant scientific advances in (i) developing a portable biosensor technology for rapid decentralized prostate cancer urinary biomarker testing and reporting, with superior performance to current clinical testing practice; and (ii) proposing a clinical validation framework (for our biosensor development) which can be ...
Kevin M. Koo +14 more
wiley +1 more source